SELLAS Life Sciences Group, Inc.
HealthcareNASDAQ:SLS · NASDAQ Capital Market
+$0.08 today
Vol 4.06M · Avg 7.80M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$26.9M +13.0% | -$30.9M +17.3% | -$37.3M +9.6% | -$41.3M -99.5% | -$20.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $0 | $0 | $0 -100.0% | $457.0K -92.0% | $5.7M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 +100.0% | -$457.0K -91.2% | -$239.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $2.0M +25.1% | $1.6M +12.5% | $1.4M -19.5% | $1.7M +70.7% | $1.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$4.1M +38.6% | -$6.6M -298.7% | $3.3M -40.7% | $5.6M +174.1% | -$7.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$535.0K +75.0% | -$2.1M -193.0% | $2.3M +89.7% | $1.2M +148.3% | -$2.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$3.5M +21.4% | -$4.5M -531.7% | $1.0M -76.4% | $4.4M +186.8% | -$5.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $597.0K +6.4% | $561.0K -53.1% | $1.2M -88.2% | $10.1M +343.2% | -$4.2M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$28.4M +19.8% | -$35.4M -12.7% | -$31.4M -31.9% | -$23.8M +8.5% | -$26.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | $0 | $0 +100.0% | -$5.5M -22.2% | -$4.5M | $0 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $0 | $0 +100.0% | -$5.5M -22.2% | -$4.5M | $0 | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $86.8M +88.1% | $46.2M +107.7% | $22.2M -7.4% | $24.0M +166.5% | $9.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$527.0K -188.7% | $594.0K +560.0% | $90.0K +5.9% | $85.0K -97.2% | $3.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $86.3M +84.6% | $46.8M +109.5% | $22.3M -7.3% | $24.1M +99.4% | $12.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $57.9M +409.9% | $11.4M +177.8% | -$14.6M -245.0% | -$4.2M +69.7% | -$13.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$28.4M +19.8% | -$35.4M +4.1% | -$36.9M -30.4% | -$28.3M -8.8% | -$26.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
SEC Filings
Recent regulatory filings
No filings found.
Does SLS generate free cash flow?
SELLAS Life Sciences Group, Inc. (SLS) generated -$28,389,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does SLS produce?
Operating cash flow was -$28,389,000.00, before capital expenditures of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.